血栓性心脑血管疾病与血小板微颗粒及其膜功能蛋白表达的关系_医学论文.docVIP

血栓性心脑血管疾病与血小板微颗粒及其膜功能蛋白表达的关系_医学论文 血栓性心脑血管疾病与血小板微颗粒及其膜功能蛋白表达的关系_医学论文 作者：苏冰，王前，孙德华，曾芳银，刘飞，张梦宇，齐涛 【关键词】 脑血管疾病；心血管疾病；血小板微颗粒；流式细胞术；CD62P,GPIIb/IIIa 　　【Abstract】 AIM: To detect platelet microparticle (PMP), glycoprotein IIb/IIIa (PAC1) and Pselection (CD62P) using whole blood flow cytometry (WBFCM) in whole blood before and after the treatment in patients with ischemic cardiovascular and cerebrovascular diseases and the activation ratio of PAC1 and CD62P, and to explore the role of PMPs, PAC1 and CD62P in the pathogenesis of thrombotic cardiovascular and cerebrovascular diseases as well as the clinical significance of detecting PMP and activation ratio of PAC1 and CD62P in whole blood in the prediction of illness state and in the prognostic evaluation. METHODS: The quantity of PMP and activation ratio of CD62P and GPIIb/IIIa were measured before and after the treatment of patient group and control group using flow cytometry. RESULTS: ① Control group PMP: (65.5±9.8)/104Plt, CD62P: (3.2±0.8)%, PAC1: (7.0±1.0)% PMP:(64.3±8.3)/104Plt, PAC1:(6.8±0.7)%, CD62P: (3.0±0.7)%, PMP:(64.3±8.2)/104Plt, PAC1:(6.8±0.7)%, CD62P:(3.0±0.7)% ② Before treatment of patient group(with thrombotic cardiovascular disease): PMP:(209.2±21.9)/104Plt, CD62P: (54.7±7.8)%, PAC1:(87.4±7.1)% After treatment: PMP:(117.9±11.9)/104Plt, CD62P:(25.2±6.3)%, PAC1:(46.2±5.1)% They were significantly higher than those in control group(0.01), and significantly lower after treatment of patient group than before treatment(0.01). ③ Before treatment of patient group(with thrombotic cerebrovascular disease): PMP:(217.3±36.6)/104Plt, CD62P:(52.8±9.3)%, PAC1:(79.9±6.8)% After treatment: PMP:(134.2±12.9)/104Plt, CD62P:(24.3±6.1)%, PAC1:(42.2±5.1)% They were significantly higher than those in control group(0.01), and significantly lower after treatment of patient group than before treatment(0.01). CONCLUSION: The levels of PMP, PAC1 and CD62P can be taken as the specificity indices for the evaluation of therapeutic efficacy